EyePoint Pharmaceuticals is approaching a critical valuation point with upcoming Phase III LUGANO trial results for its DURAVYU treatment targeting wet age-related macular degeneration (AMD), expected by August 2026. The trial focuses on sustained six-month dosing, broad patient inclusion, and direct comparison to the current standard treatment aflibercept, highlighting its potential commercial relevance. EyePoint also owns its manufacturing infrastructure and a drug delivery platform applicable to multiple retinal diseases, strengthening its market position. The company’s cash runway extends through late 2027, but additional funding will be necessary, with positive trial outcomes likely improving fundraising conditions.
Snowflake reported strong Q2 2026 results with earnings per share of $0.62, beating estimates of $0.45, and revenue of $1.55 billion, surpassing the expected $1.48 billion. The company achieved a 35% year-over-year revenue increase, driven by its rol...
On September 2, 2026, several small-cap stocks and leveraged ETFs saw significant gains. bioAffinity Technologies surged 47.5% amid volatility and recent clinical updates, while Focus Universal rose 33.7% likely due to speculative trading. Swvl Holdi...
Several tech stocks including Pasqal, Credo, Palo Alto Networks (PANW), FuelCell Energy (FCEL), and MongoDB (MDB) saw significant declines on September 2, 2026. Pasqal dropped over 21% despite positive quantum computing progress, likely due to profit...
Scienjoy Holding Corporation announced it will acquire a 29.9% stake in Leader Education Limited for approximately $13.1 million through its subsidiary. The deal aims to combine Scienjoy's AI and technology capabilities with Leader Education's privat...
Rosen Law Firm is investigating potential securities claims for UP Fintech shareholders following allegations that the company issued misleading business information. This comes after a May 2026 Reuters report about China's crackdown on illegal cross...
